AMLOGENYX Trademark

Trademark Overview


On Wednesday, September 11, 2024, a trademark application was filed for AMLOGENYX with the United States Patent and Trademark Office. The USPTO has given the AMLOGENYX trademark a serial number of 98745222. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Friday, March 21, 2025. This trademark is owned by Amlogenyx Inc.. The AMLOGENYX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases and disorders, neurological diseases and disorders, gene therapy, and cell therapy; biomedical research in the field of gene therapy design and delivery; new product design services in the field of gene therapy; product development of biochemical assays; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of neurological and genetic diseases and disorders; med...
amlogenyx

General Information


Serial Number98745222
Word MarkAMLOGENYX
Filing DateWednesday, September 11, 2024
Status680 - APPROVED FOR PUBLICATION
Status DateFriday, March 21, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases and disorders, neurological diseases and disorders, gene therapy, and cell therapy; biomedical research in the field of gene therapy design and delivery; new product design services in the field of gene therapy; product development of biochemical assays; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of neurological and genetic diseases and disorders; medical and scientific research information in the field of neurological and genetic diseases and disorders; providing medical research and scientific research information in the field of neurological and genetic diseases and disorders; providing medical research and scientific research information in the field of gene therapies

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, September 11, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmlogenyx Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNovato, CA 94949

Trademark Events


Event DateEvent Description
Wednesday, September 11, 2024NEW APPLICATION ENTERED
Friday, January 24, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 12, 2025ASSIGNED TO EXAMINER
Friday, March 14, 2025NON-FINAL ACTION E-MAILED
Friday, March 14, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 14, 2025NON-FINAL ACTION WRITTEN
Wednesday, March 19, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 19, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 19, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 21, 2025APPROVED FOR PUB - PRINCIPAL REGISTER